Ογκολογία Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment Authors: Kyle Nolla et al. 01/07/2023 time to read < 1 min read
Ογκολογία An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma Authors: Matteo Rosellini et al. 01/04/2023 time to read 2 min read
Ογκολογία Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study Authors: Toni K Choueiri et al. 01/03/2023 time to read 3 min read
Ογκολογία The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma Authors: Jens Bedke et al. 01/01/2023 time to read 2 min read
Ογκολογία Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma Authors: Jens Bedke et al 01/10/2022 time to read 2 min read
Ογκολογία Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma Authors: Toni K Choueiri et al. 19/08/2021 time to read 2 min read
Ογκολογία Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma Authors: Robert Motzer et al. 08/04/2021 time to read 2 min read